Cat. No.: DAB-0011966
Product Information | |
---|---|
Clonality | Polyclonal |
Host Species | Rabbit |
Reactivity | Human |
Applications | WB |
Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly301 of human DHODH protein. Antibodies are purified by peptide affinity chromatography. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | DHODH |
UniProt No. | Q02127 |
Gene ID | 1723 |
Gene Description | Dihydroorotate dehydrogenase catalyzes the conversion of dihydroorotate to orotate in pyrimidine biosynthesis. DHODH was shown to be a metabolic regulator of myeloid differentiation in AML models. Inhibition of this enzyme triggers myeloid differentiation, decreases leukemic cell burden, and prolongs survival. In addition, research studies show that pyrimidine biosynthesis mediated by DHODH is critical for tumorigenesis. Cancer cells deleted of DHODH fail to form tumors, suggesting DHODH as a potential target in cancer therapy. Further studies also indicate that loss of DHODH diminishes tumor growth in vivo. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.